We observed that stable knockout of SLC3A2 and SLC7A5 effectively inhibited tumor growth in vivo, as reflected by a significant reduction in tumor size and growth rate compared to non-target CRISPR-V2 controls (Fig. 3I–L). This evidence concerns the gene SLC3A2 and neoplasm.